<DOC>
	<DOCNO>NCT01822561</DOCNO>
	<brief_summary>- The goal study examine short-term effect safety systemic anti-aldosterone medication , eplerenone , small group patient central serous chorioretinopathy ( CSCR ) . - There currently standard treatment therapy either acute chronic CSCR , potentially debilitate eye disease . - There evidence animal human high blood serum corticosteroid level cause worsen CSCR finding similar CSCR choroid retina - Eplerenone , mineralocorticoid receptor antagonist , show visual anatomic benefit small series 4 patient chronic CSCR , suggest decrease mineralocorticoid action eye may improve sign symptom CSCR - The investigator ' aim evaluate standardize dose eplerenone control prospective fashion acute chronic CSCR . - The study consist take standard dose eplerenone , 50mg daily , 1 month - Over course month , patient monitor side effect , well visual anatomical response medication</brief_summary>
	<brief_title>Eplerenone Central Serous Chorioretinopathy</brief_title>
	<detailed_description>- The investigator hypothesize aldosterone inhibition eplerenone decrease choroidal vessel vasodilation , focal leakage , choroidal thickness patient acute chronic CSCR , lead resolution subretinal fluid ultimately improvement symptom . - Resolution sub-retinal fluid primary outcome , precisely measure use optical coherence tomography ( OCT ) - Secondary outcome include : Change macular thickness measure OCT , central macular circle thickness OCT , change visual acuity , change dye leakage characteristic fluorescein angiography , change OCT characteristic fellow eye , safety tolerability characteristic - In acute CSCR , subretinal fluid often resolve , often take several month ( literature show ~20 % patient complete resolution sub-retinal fluid OCT 1 month presentation ) - Chronic CSCR define persistent fluid OCT 3 month symptom onset , recurrence sign symptom within 1 year prior episode - In study , investigator make distinction acute chronic CSCR - Eplerenone , generic medication , potassium spar diuretic , FDA approve treat heart failure well high blood pressure , FDA approve treatment central serous chorioretinopathy . - The important side effect eplerenone elevation serum potassium decrease blood pressure - Patients therefore screen routine blood test suggest package insert medication , serum potassium blood pressure monitor routinely direct medication package insert - Study visit perform therapy initiation , 1 week , 2 week , 4 week</detailed_description>
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>1 . Age 18 2 . Ability give write informed consent 3 . Presence subretinal fluid fovea see OCT 4 . Diagnosis Acute Chronic CSCR : Acute CSCR : First presentation eye clinic visual symptom , include decrease vision visual distortion , characteristic appearance CSCR examination , fluorescein angiography , OCT . Chronic CSCR : Previous diagnosis CSCR , persistent subretinal fluid OCT 3 month initial presentation eye clinic , &lt; 50 % reduction fluid thickness OCT 3 month . Patients previous treatment CSCR may include . 1 . Age less 18 2 . Persons impair decisionmaking ability . 3 . Women know pregnant actively try conceive . 4 . Additional eye disease affect macula posterior retina . 5 . At screening , serum potassium concentration â‰¥5.0 mEq/L , serum creatinine concentration &gt; 2 mg/dL men &gt; 1.8 mg/dL woman , creatinine clearance &lt; 50 mL/min , concomitant administration potassium supplement , potassiumsparing diuretic , and/or potent CYP3A4 inhibitor ( amifostine , cyclosporine , fluconazole , itraconazole , ketoconazole , mifepristone , posaconazole , potassium salt , Rituximab , tacrolimus voriconazole ) . 6 . Patients type 2 diabetes screen microalbuminuria urinalysis . If microalbuminuria present , patient exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Central Serous Chorioretinopathy</keyword>
	<keyword>Eplerenone</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>Enhanced Depth Imaging</keyword>
	<keyword>Subretinal Fluid</keyword>
</DOC>